The price-to-earnings ratio for Boston Scientific Corp. (NYSE: BSX) is above average at 63.78x. The 36-month beta value for BSX is also noteworthy at 0.79. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 10 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
The public float for BSX is 1.46B, and at present, short sellers hold a 0.91% of that float. The average trading volume of BSX on June 17, 2024 was 5.85M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BSX) stock’s latest price update
Boston Scientific Corp. (NYSE: BSX) has experienced a decline in its stock price by -0.55 compared to its previous closing price of 76.76. However, the company has seen a fall of -1.40% in its stock price over the last five trading days. zacks.com reported 2024-06-14 that Investors looking for stocks in the Medical – Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
BSX’s Market Performance
Boston Scientific Corp. (BSX) has seen a -1.40% fall in stock performance for the week, with a 2.39% gain in the past month and a 13.52% surge in the past quarter. The volatility ratio for the week is 1.09%, and the volatility levels for the past 30 days are at 1.26% for BSX. The simple moving average for the past 20 days is 0.57% for BSX’s stock, with a 23.32% simple moving average for the past 200 days.
Analysts’ Opinion of BSX
Many brokerage firms have already submitted their reports for BSX stocks, with Goldman repeating the rating for BSX by listing it as a “Buy.” The predicted price for BSX in the upcoming period, according to Goldman is $90 based on the research report published on May 30, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see BSX reach a price target of $80, previously predicting the price at $65. The rating they have provided for BSX stocks is “Buy” according to the report published on February 01st, 2024.
Robert W. Baird gave a rating of “Outperform” to BSX, setting the target price at $59 in the report published on July 19th of the previous year.
BSX Trading at 4.64% from the 50-Day Moving Average
After a stumble in the market that brought BSX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.68% of loss for the given period.
Volatility was left at 1.26%, however, over the last 30 days, the volatility rate increased by 1.09%, as shares surge +2.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.39% upper at present.
During the last 5 trading sessions, BSX fell by -1.36%, which changed the moving average for the period of 200-days by +40.72% in comparison to the 20-day moving average, which settled at $75.99. In addition, Boston Scientific Corp. saw 32.04% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BSX starting from Carruthers Wendy, who sale 6,983 shares at the price of $75.33 back on Jun 03 ’24. After this action, Carruthers Wendy now owns 45,628 shares of Boston Scientific Corp., valued at $526,029 using the latest closing price.
Mirviss Jeffrey B., the EVP&Pres, Periph Intervent of Boston Scientific Corp., sale 63,802 shares at $75.10 during a trade that took place back on May 29 ’24, which means that Mirviss Jeffrey B. is holding 28,022 shares at $4,791,447 based on the most recent closing price.
Stock Fundamentals for BSX
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.69 for the gross margin
The net margin for Boston Scientific Corp. stands at 0.12. The total capital return value is set at 0.08. Equity return is now at value 9.38, with 5.09 for asset returns.
Based on Boston Scientific Corp. (BSX), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at 0.23. The debt to equity ratio resting at 0.55. The interest coverage ratio of the stock is 9.2.
Currently, EBITDA for the company is 3.62 billion with net debt to EBITDA at 2.4. When we switch over and look at the enterprise to sales, we see a ratio of 8.21. The receivables turnover for the company is 6.38for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.66.
Conclusion
In summary, Boston Scientific Corp. (BSX) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
